| 1 |
34521333 | An Update of the Efficacy and Comparative Characteristics of Direct (New) Oral Anticoagulants (DOACs). | 2022 |
1 |
| 2 |
34864841 | Utilization of apixaban anti-Xa levels in transition from apixaban to warfarin in a patient with chronic renal dysfunction. | 2022 Apr 19 |
1 |
| 3 |
35135308 | MRI-Detected Brain Lesions and Cognitive Function in Patients With Atrial Fibrillation Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 Trial. | 2022 Mar 22 |
1 |
| 4 |
35455642 | Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting. | 2022 Mar 24 |
1 |
| 5 |
35507109 | Andexanet alfa after 4-factor PCC administration for intracranial hemorrhage: a case series. | 2022 May 4 |
1 |
| 6 |
31746285 | Four-Factor Prothrombin Complex Concentrate for the Reversal of Direct Oral Anticoagulants. | 2021 Jan |
1 |
| 7 |
32458320 | Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction. | 2021 Oct |
3 |
| 8 |
32651897 | Apixaban Downregulates Endothelial Inflammatory and Prothrombotic Phenotype in an In Vitro Model of Endothelial Dysfunction in Uremia. | 2021 Jun |
1 |
| 9 |
32946681 | Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory. | 2021 Feb |
1 |
| 10 |
33106093 | Cytosorb® hemoadsorption of apixaban during emergent cardio-pulmonary bypass: a case report. | 2021 Nov |
1 |
| 11 |
33243038 | An update on the efficacy and safety of novel anticoagulants for cancer associated thrombosis. | 2021 Apr |
1 |
| 12 |
33351142 | Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study. | 2021 Apr 26 |
1 |
| 13 |
33367661 | The Effect of Direct Oral Anticoagulants on Antithrombin Activity Testing Is Abolished by DOAC-Stop in Venous Thromboembolism Patients. | 2021 Jan 1 |
1 |
| 14 |
33493142 | A 78-Year-Old Man with a Pulmonary Embolism Who Developed Skin Necrosis 7 Days After Treatment with the Direct Oral Anticoagulant Factor Xa Inhibitor Apixaban. | 2021 Jan 25 |
1 |
| 15 |
33529664 | Influence of age on the relationship between apixaban concentration and anti-factor Xa activity in older patients with non-valvular atrial fibrillation. | 2021 May 15 |
6 |
| 16 |
33640261 | Controversies: Stroke Prevention in Chronic Kidney Disease. | 2021 Sep |
2 |
| 17 |
33685912 | Treatment with the direct oral anticoagulants (DOACs) apixaban and rivaroxaban associated with significant worsening of behavioural and psychological symptoms of dementia (BPSD). | 2021 Mar 8 |
1 |
| 18 |
33856296 | Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding. | 2021 Feb 26 |
1 |
| 19 |
33870027 | Apixaban in low-weight patients with cancer-associated thrombosis: A cross sectional study of drug levels. | 2021 Mar |
1 |
| 20 |
33966491 | Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy. | 2021 Jun |
2 |
| 21 |
34145954 | Effectiveness of apixaban versus enoxaparin in preventing wound complications and deep venous thrombosis following total knee replacement surgery: A retrospective study. | 2021 Oct |
1 |
| 22 |
34233467 | Clinical Outcomes in Atrial Fibrillation Patients With a History of Cancer Treated With Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Cohort Study. | 2021 Oct |
1 |
| 23 |
34291105 | Pharmacokinetics and Biologic Activity of Apixaban in Healthy Dogs. | 2021 |
1 |
| 24 |
34342172 | Apixaban Single-Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration. | 2021 Sep |
3 |
| 25 |
34363188 | Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment. | 2021 Dec |
1 |
| 26 |
34749042 | High-dose versus low-dose 4-factor prothrombin complex concentrate for factor Xa inhibitor reversal in intracranial hemorrhage. | 2021 Dec |
1 |
| 27 |
34807769 | Managing patients on direct factor Xa inhibitors with rapid thrombelastography. | 2021 Dec |
1 |
| 28 |
34894638 | Factor Xa Inhibitors for Patients after Mechanical Heart Valve Replacement? | 2021 Dec 11 |
1 |
| 29 |
30614371 | A Systematic and Evidence-Based Review of Published and Pending Reports of Andexanet Alfa. | 2020 Aug |
1 |
| 30 |
31286666 | Interlaboratory validation of apixaban levels in ex vivo patient samples using a chromogenic anti-factor Xa assay. | 2020 Feb |
1 |
| 31 |
31520364 | Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study. | 2020 Feb |
1 |
| 32 |
31564018 | Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care. | 2020 Feb |
1 |
| 33 |
31831187 | Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents. | 2020 Feb |
2 |
| 34 |
31839722 | Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations. | 2020 Feb 15 |
1 |
| 35 |
31877292 | Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve-Induced Thrombin Generation. | 2020 Aug |
1 |
| 36 |
31958251 | A comprehensive evaluation of apixaban in the treatment of venous thromboembolism. | 2020 Feb |
1 |
| 37 |
32338333 | Factor Xa inhibitors in patients with continuous-flow left ventricular assist devices. | 2020 Nov |
1 |
| 38 |
32480336 | Atraumatic splenic rupture in a patient treated with apixaban: A case report. | 2020 |
1 |
| 39 |
32676543 | Bleeding Risk in Nonvalvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants and Warfarin: A Systematic Review and Meta-Analysis of Observational Studies. | 2020 Jul |
1 |
| 40 |
32685886 | Antiviral anticoagulation. | 2020 Jul |
1 |
| 41 |
32693197 | Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve. | 2020 Sep |
1 |
| 42 |
33062596 | Perinephric Hematoma Induced by Factor Xa Inhibitor in a Patient with a Vascular Renal Mass. | 2020 Sep |
1 |
| 43 |
33209349 | Synthesis, crystal structure, Hirshfeld surface analysis, MEP study and mol-ecular docking of N-{3-[(4-meth-oxy-phen-yl)carbamo-yl]phen-yl}-3-nitro-benzamide as a promising inhibitor of hfXa. | 2020 Nov 1 |
1 |
| 44 |
33313467 | Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation. | 2020 Nov |
1 |
| 45 |
33337539 | Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. | 2020 Dec 18 |
1 |
| 46 |
29757137 | Reversal of apixaban induced alterations in haemostasis by different coagulation factor concentrates in patients after hip or knee replacement surgery. | 2019 Mar |
1 |
| 47 |
30321554 | Non-vitamin K oral anticoagulants (NOAC) and the risk of myocardial infarction: Differences between factor IIa and factor Xa inhibition? | 2019 Mar |
1 |
| 48 |
30421320 | Recurrent venous thromboembolism in primary membranous nephropathy despite direct Xa inhibitor therapy. | 2019 Aug |
1 |
| 49 |
30698331 | An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays. | 2019 Jun |
1 |
| 50 |
30730782 | Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. | 2019 Apr 4 |
1 |